[ad_1]
Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.
[ad_2]
Source link
Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Published on:
